Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 6/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18293014 | 0.90 | PDK1 (0.41) | PDK1CACNA1HDRD3HRH3HDAC6 | |
| SCHEMBL22123162 | 0.85 | CARM1 (0.42) | CARM1PRMT6PRMT8PRMT1CACNA1H | |
| SCHEMBL23328919 | 0.81 | DRD3 (0.49) | PDK1DRD3 | |
| SCHEMBL22123875 | 0.81 | CARM1 (0.39) | CARM1PRMT6PRMT8PRMT1CACNA1H | |
| SCHEMBL22879240 | 0.78 | PDK1 (0.44) | PDK1DRD3HRH3LRRK2 | |
| SCHEMBL3428332 | 0.77 | PDK1 (0.46) | PDK1DRD3HRH3HDAC6 | |
| SCHEMBL3424587 | 0.77 | PDK1 (0.46) | PDK1DRD3HRH3HDAC6 | |
| SCHEMBL29048494 | 0.77 | PDK1 (0.46) | PDK1DRD3HRH3LRRK2 | |
| SCHEMBL22052974 | 0.77 | CACNA1H (0.36) | CARM1PRMT6PRMT8PRMT1CACNA1H | |
| SCHEMBL19488377 | 0.77 | PDK1 (0.49) | PDK1DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | PDK1 1826/4885CARM1 262/4885PRMT6 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.